Determination of molecular marker expression can predict clinical outcome in colon carcinomas

被引:97
作者
Galizia, G
Lieto, E
Ferraraccio, F
Orditura, M
De Vita, F
Castellano, P
Imperatore, V
Romano, C
Ciardiello, F
Agostini, B
Pignatelli, C
机构
[1] Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Surg Oncol, I-80131 Naples, Italy
[2] Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Pathol, I-80131 Naples, Italy
[3] Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Med Oncol, I-80131 Naples, Italy
[4] Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Internal Med Allergy & Clin Immunol, I-80131 Naples, Italy
关键词
D O I
10.1158/1078-0432.CCR-0960-03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional staging procedures are often unable to precisely predict prognosis in colorectal cancer (CRC). In this study, we set out to investigate the possible role of molecular/structural indicators involved in cell cycle regulation (p27 and p53), apoptosis (p53 and p27), and tumor neoangiogenesis [p53, vascular endothelial growth factor (VEGF), and microvessel count] in predicting tumor behavior and clinical outcome in CRC patients Experimental Design: Analysis of the above indicators was performed by immunohistochemistry on 104 CRC patient samples and 25 normal colon mucosa specimens. Results: Intense p27 nuclear staining was found in normal colon mucosa, with p53 nuclear staining and VEGF cytoplasmic accumulation <10%, and low microvessel count. In contrast, in CRC samples, p27 was down-regulated in 53.8%, p53 protein was overexpressed in 52%, and VEGF stained positive in 67.3% of the cases, respectively. Multiple regression analysis showed that molecular markers were strongly correlated. In patients treated with curative surgery, a significant relationship was seen between p27 down-regulation and Dukes' stage, nodal status, and the presence of distant metastases. VEGF overexpression correlated significantly with Dukes' stage, tumor (t) and metastasis (m) parameters, and left site. Stepwise regression selected p27, p53, VEGF, and Dukes' stage as the best combination of variables capable of predicting both disease-specific and disease-free survival. C Conclusions: The investigated indicators may be useful for the prediction of outcome and recurrence rate in curatively treated CRC patients. In conjunction with clinical and pathological staging, they may provide a stronger indication of clinical outcome than staging alone and help better select therapeutic options in CRC patients.
引用
收藏
页码:3490 / 3499
页数:10
相关论文
共 40 条
[1]   Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study [J].
Allegra, CJ ;
Paik, S ;
Colangelo, LH ;
Parr, AL ;
Kirsch, I ;
Kim, G ;
Klein, P ;
Johnston, PG ;
Wolmark, N ;
Wieand, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :241-250
[2]  
[Anonymous], 2002, AJCC CANC STAGING MA, P113
[3]  
Arber N, 1999, CANCER EPIDEM BIOMAR, V8, P1101
[4]   Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? [J].
Bazan, V ;
Migliavacca, M ;
Tubiolo, C ;
Macaluso, M ;
Zanna, I ;
Corsale, S ;
Amato, A ;
Calò, V ;
Dardanoni, G ;
Morello, V ;
La Farina, M ;
Albanese, I ;
Tomasino, RM ;
Gebbia, N ;
Russo, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 191 (02) :237-246
[5]   Should Dukes' B patients receive adjuvant therapy? A statistical perspective [J].
Buyse, M ;
Piedbois, P .
SEMINARS IN ONCOLOGY, 2001, 28 (01) :20-24
[6]  
Cascinu S, 2000, CLIN CANCER RES, V6, P2803
[7]   An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation [J].
Cascinu, S ;
Graziano, F ;
Catalano, V ;
Staccioli, MP ;
Rossi, MC ;
Baldelli, AM ;
Barni, S ;
Brenna, A ;
Secondino, S ;
Muretto, P ;
Catalano, G .
BRITISH JOURNAL OF CANCER, 2002, 86 (05) :744-749
[8]  
Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO
[9]  
2-T
[10]   Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines [J].
Duffy, MJ ;
van Dalen, A ;
Haglund, C ;
Hansson, L ;
Klapdor, R ;
Lamerz, R ;
Nilsson, O ;
Sturgeon, C ;
Topolcan, O .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :718-727